Buparvaquone

Abstract

Theileriosis is a type of blood protozoan infection caused by the transmission of Theileria spp. species in tropical and subtropical regions by ticks belonging to the Ixodidae family. The disease progresses with high mortality and morbidity especially in ruminants. While deaths are observed in the first few days in peracute cases, it is reported that deaths are observed within the first weeks in acute cases. Fever, lymphadenopathy, respiratory distress, increase in heart rate, decrease in milk yield, weight loss, abortion and death are observed in patients. Buparvaquone, an antiprotozoal drug of the hydroxynaphthoquinone group, is the single most effective drug used in the treatment of the disease. Although it is recommended to use 2.5 mg/kg intramuscularly against theileriosis infection in cattle, it can be used in the same dosage regimen 2-3 days later if deemed necessary by the physician. In case of use of the drug, local reactions may develop in the area where it is applied, and it is not recommended to be used with vaccines and in pregnant animals. The drug is generally considered safe. Since the disease is transmitted by ticks, it is recommended to add an ectoparasitic agent to the treatment protocol. In this review, it has been tried to give information about the use of buparvaquone in the treatment of theileriosis.